OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

Preclinical data to be presented by Dr. Gastón Soria, Co-Founder and Chief Scientific Officer, will highlight: Preclinical data to be presented by Dr. Gastón Soria, Co-Founder and Chief Scientific Officer, will highlight: "The selection of ONC001 for an oral presentation at ASH underscores the strength of this fundamentally new therapeutic approach," saidTarek Zaki, Co-Founder & Chief Executive Officer of OncoPrecision. "ONC001 is designed to specifically target resistance mechanisms...

NEW YORK, 01/12/2025 (informazione.news - comunicati stampa - salute e benessere)

Preclinical data to be presented by Dr. Gastón Soria, Co-Founder and Chief Scientific Officer, will highlight:

"The selection of ONC001 for an oral presentation at ASH underscores the strength of this fundamentally new therapeutic approach," said Tarek Zaki, Co-Founder & Chief Executive Officer of OncoPrecision. "ONC001 is designed to specifically target resistance mechanisms that drive certain aggressive blood cancers, offering a new way to overcome common treatment failures. We look forward to sharing this data with the global hematology community and to continuing discussions with prospective development and strategic partners."

"ONC001 is the direct result of our platform's ability to integrate insights from patient-derived biology with rational target selection and payload matching," said Dr. Gastón Soria. "Although CD64 has long been acknowledged as a biomarker of monocytic leukemia, no approved or clinical-stage assets have successfully exploited it as a therapeutic target. Our platform unveiled that an ADC modality is the optimal path to achieve this."

Oral Presentation Details

About OncoPrecision

OncoPrecision is a next-generation oncology therapeutics company leveraging large-scale, patient-derived biology and AI-enhanced discovery platforms to develop precision medicines with a higher probability of clinical success. The company integrates translational biology, machine learning, and modular ADC/BsAb engineering to build a pipeline of first-in-class interventions across hematologic malignancies and solid tumors. The company is actively exploring strategic collaborations and partnerships to accelerate the development and commercialization of its programs.

Forward-Looking Statements

This press release contains forward-looking statements regarding the development, safety, and therapeutic potential of ONC001 and other product candidates. Actual results may differ materially from those expressed or implied due to risks and uncertainties inherent in drug development. OncoPrecision undertakes no obligation to update or revise these statements.

Contact Information

For general inquiries, please contact:

info@oncoprecision.bio

For business development inquiries, please contact:

bd@oncoprecision.bio 

Logo - https://mma.prnewswire.com/media/2833022/OncoPrecision_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/oncoprecision-announces-oral-presentation-of-onc001-a-first-in-class-cd64-targeting-adc-for-monocytic-leukemia-at-the-67th-ash-annual-meeting-302627021.html